Details
Site：homepage  Details  faculty
Liang Han
Publisher：管理员LI  Time2016-12-23 View:80

Liang Han

PhD, Associate Professor

Phone: 86-18646092163

Email: lianghan@hit.edu.cn

Research Area: Biomedical Engineering, Pharmaceutics and Targeted Drug Delivery System

Join: http://life.hit.edu.cn/news/show.asp?id=4929

___________________________________________________________________________________

Dr. Liang Han, earned his Ph.D. in Pharmaceutics at Fudan University in 2012. At Yale University School of Medicine, the Department of Neurosurgery, he undertook 3-year training for Biomedical Engineering Research, as a Postdoctoral Associate. He joined the School of Life Science and Technology at Harbin Institute of Technology as anassociate professor in 2015.

The research emphasis in his lab is mainly put on the systemic drug delivery systems for targeted and controllable delivery to brain, cancers, diabetes and obesity. The details are:

1) Targeted delivery of the CRISPR/CAS systems

2)Targeted delivery of H2O2/O2- and pH- dual-dependent fluorescence system for tumor imaging

3) Tumor microenvironment-responsive micelles to overcome the IFP for targeted tumor delivery

4) The design of polypeptide for treatment of diabetes and obesityand so on……

Achievements:

He has published 20 SCI peer-reviewed research papers in top SCI journals including Advanced Materials, Small, Biomaterials, Advanced Healthcare Materials, and Molecular Pharmaceutics. Of all, 7 SCI research papers were first-authored (Small, Biomaterials, Advanced Healthcare Materials, and Molecular Pharmaceutics). The sum of impact factor for these first-authored papers is 46.692. These first-authored papers have been cited over 272 times. Another 2 first-authored research papers are under consideration in ACS Nano and Biomaterials. He published 1 review paper in core journal in Chinese, file 1 US patents and was granted 6 China patents. Heis an academic editor for Medicine Journal and reviewer for Biomaterials and Journal of Controlled Release. He also received travel award from Eli Lilly Company as unique Asian student (1/3, worldwide) for attending “the 25th American Association of Pharmaceutical Scientists Annual Meeting” in 2011, gave poster presentation during the conference, and got high approval from experts. 

Experience:

He joined Professor Chen Jiang’s lab at School of Pharmacy, Fudan University for Ph.D. study in September 2007. He had been developing noninvasive administration approaches for cancer diagnosis and treatment. Especially, his research was emphasized on overcoming the following scientific questions including, 1) the tumor targeting efficiency of transferrin is susceptible to be competitively inhibited by endogenous transferrin; 2) clinical MRI contrast agent gadolinium-DTPA doesn’t enter tumor cells and detects tumor based on angiography, resulting the quick elimination from the blood; 3) encapsulation of anticancer drug Doxorubicin inside the nanoparticles through hydrophobic interaction shows uncontrollable release, leading unwanted release inside the blood and side effects; 4) the combination therapy between gene and chemotherapy drug needs separate preparation of respective delivery systems; 5) tumor active-targeting delivery systems often accumulate in normal tissues and lead to side effects due to the expression of targeting receptors/transporters in normal cells. To answer these questions, He proposed three strategies including, 1) the combination of EPR effect and tumor extracellular acidic microenvironments; 2) the combination of EPR effect and receptor-mediated active targeting; 3) the combination of EPR effect, tumor extracellular acidic microenvironments and receptor-mediated active targeting. Based on these three strategies, He designed drug delivery systems targeting liver cancer and brain cancer for early diagnosis and therapy. During the five years, He had proven to be exceptional in Pharmaceutics and Biomedical Engineering, especially in targeted drug delivery field, which is substantiated by his numerous publications in top journals and many distinguished awards. In June 2012, He was granted the degree of Ph.D. His dissertation was awarded as outstanding doctoral dissertation in June 2014.

He went to Yale University and joined Professor Jiangbing Zhou’s lab at Department of Neurosurgery, School of Medicine as a postdoctoral associate in September 2012. During this period, He proposed autocatalytic brain targeting nanotechnology to overcome the blood brain barrier for brain targeting delivery. He has been involved in and led several research projects, including: 1) Autocatalytic delivery of nanoparticles for brain cancer diagnosis and therapy; 2) Autocatalytic delivery of nanoparticles for treatment of ischemic stroke; 3) Responsive micelles for systemic delivery of chemotherapy to brain tumors; 4) Magnetic-guided controlled gene therapy for brain cancer; and 5) Self-assembling polypeptide nanoparticles for treatment of ischemic stroke. Two manuscripts based on the first two projects are currently in revision in ACS Nano and Biomaterials. A provisional patent regarding the autocatalytic brain targeting nanotechnology has also been filed.

Publications:

  • Han L, Derek K. Kong, Mingqiang Zheng, Sasidhar Murikinati, Liyuan Li, Daofeng Tian, Qiang Cai, Chunlin Ye, Daniel Holden, June-Hee Park, Xiaobin Gao, Jean-Leon Thomas, Jaime Grutzendler, Richard E. Carson, Yiyun Huang, Joseph M. Piepmeier, Jiangbing Zhou. Autocatalytic drug delivery for brain cancer imaging and therapy. (ACS Nano, in revision)

  • Han L, Qiang Cai, Daofeng Tian, Derek K. Kong, Xingchun Gou, Stephen M. Strittmatter, Kevin N. Sheth, Jiangbing Zhou. A novel combinatorial approach for systemic drug delivery to stroke. (Biomaterials, in revision)

  • Han L, Liu M, Ye D, Zhang N, Lim E, Lu J, Jiang C. Tumor cell membrane-targeting pH-dependent electron donor-acceptor fluorescence systems with low background signals. Biomaterials, 2014, 35(9):2952-2960.

  • Han L, Guo Y, Ma H, He X, Kuang Y, Zhang N, Lim E, Zhou W, Jiang C. Acid Active Receptor-Specific Peptide Ligand for In Vivo Tumor-Targeted Delivery. Small, 2013, 9(21):3647-3658.

  • Han L, Ma H, Guo Y, Kuang Y, He X, Jiang C. pH-Controlled Delivery of Nanoparticles into Tumor Cells. Adv Healthc Mater, 2013, 2(11):1435-1439.

  • Han L, Li JF, Huang SX, Huang RQ, Liu SH, Hu X, Yi PW, Shan D, Wang XX, Lei H, Jiang C. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. Biomaterials, 2011, 32(11):2989-2998.

  • Han L, Huang R, Li J, Liu S, Huang S, Jiang C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials, 2011, 32(4):1242-1252.

  • Han L, Huang R, Liu S, Huang S, Jiang C. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol Pharm, 2010, 7(6):2156-2165.

  • Han L, Huang RQ, Jiang C. Theranostic tumor-targeted nanoscale delivery systems. Journal of International Pharmaceutical Research, 2011, 38(5):362-368.

  • Huang RQ, Han L (co-first author), Li JH, Ren FL, Ke WL, Jiang C, Pei YY. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. J Gene Med, 2009, 11(9):754-763.

  • Strohbehn G, Coman D, Han L, Ragheb RR, Fahmy TM, Huttner AJ, Hyder F, Piepmeier JM, Saltzman WM, Zhou J. Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance. J Neurooncol, 2015, 121(3):441-449.

  • Huang R, Ma H, Guo Y, Liu S, Kuang Y, Shao K, Li J, Liu Y, Han L, Huang S, An S, Ye L, Lou J, Jiang C. Angiopep-conjugated nanoparticles for targeted long-term gene therapy of Parkinson's disease. Pharm Res, 2013, 30(10):2549-2559.

  • Liu S, Guo Y, Huang R, Li J, Huang S, Kuang Y, Han L, Jiang C. Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials, 2012, 33(19):4907-4916.

  • Li J, Zhou L, Ye D, Huang S, Shao K, Huang R, Han L, Liu Y, Liu S, Ye L, Lou J, Jiang C. Choline-Derivate-Modified Nanoparticles for Brain-Targeting Gene Delivery. Adv Mater, 2011, 23(39):4516-4520.

  • Huang S, Li J, Han L, Liu S, Ma H, Huang R, Jiang C. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. Biomaterials, 2011, 32(28):6832-6838.

  • Huang RQ, Han L, Li JF, Liu SH, Shao K, Kuang YY, Hu X, Wang XX, Lei H, Jiang C. Chlorotoxin-modified Macromolecular Contrast Agent for MRI Tumor Diagnosis. Biomaterials, 2011, 32(22):5177-5186.

  • Huang RQ, Ke WL, Han L, Li JF, Liu SH, Jiang C. Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. Biomaterials, 2011, 32(9):2399-2406.

  • Shao K, Huang RQ, Li JF, Han L, Ye LY, Lou JN, Jiang C. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J Control Release, 2010, 147(1):118-126.

  • Huang RQ, Liu SH, Shao K, Han L, Ke WL, Liu Y, Huang SX, Jiang C. Evaluation and mechanism studies of PEGylated dendrigraft poly-L-lysines as novel gene delivery vectors. Nanotechnology, 2010, 21(26):265101.

  • Huang RQ, Ke WL, Han L, Liu Y, Shao K, Jiang C, Pei Y Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res Bull, 2010, 81(6):600-604.

  • Liu Y, Huang RQ, Han L, Ke WL, Shao K, Ye LY, Lou JN, Jiang C. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials, 2009, 30(25):4195-202.

  • Ke WL, Shao K, Huang RQ, Han L, Liu Y, Li JF, Kuang YY, Ye LY, Lou JN, Jiang C. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials, 2009, 30(36):6976-6985.

  • Huang RQ, Ke WL, Han L, Liu Y, Shao K, Ye LY, Lou JN, Jiang C, Pei YY. Brain-targeting mechanisms of lactoferrin-modified DNA-loaded nanoparticles. J Cereb Blood Flow Metab, 2009, 29(12):1914-1923.

Authorized patents：

  • HAN LIANG, JIANG CHEN, HUANG RONGQIN, KE WEILUN.Polypeptide-modified liver tumor-targeted nano medicine delivery system and preparation method thereof(China patent 200910198450.5).

  • HAN LIANG, JIANG CHEN, HUANG RONGQIN.Tumor-targeted diagnosis nuclear magnetic resonance contrast agent and preparation method thereof (China patent 201010286508.4).

  • HAN LIANG, JIANG CHEN. Tumor active targeting nano drug delivery system controlled by slightly acidic environment, and preparation method thereof (China patent 201210380988.X).

  • JIANG CHEN, HAN LIANG, HUANG RONGQIN. Tumor-targeting double-drug carrying and delivery system and preparation method thereof (China patent 201010286479.1).

  • HAN LIANG, JIANG CHEN.Slightly acidic environment targeted polypeptide modified tumor targeted nano drug delivery system, and preparation method thereof (China patent2012103809907).

Filed patents：

  • “Compositions for Enhancing Delivery of Agents Across the Blood Brain Barrier and Methods of Use Thereof”, Jiangbing Zhou, Liang Han and Joseph M. Piepmeier, US Provisional Patent No. 62/147942, Filed April 15, 2015.